Genetically engineered fusion proteins for treatment of cancer

Cancer Genomics and Proteomics

Volumn 9, Issue 6, 2012, Pages 357-372

  Weidle, Ulrich H ^a   Schneider, Britta ^a   Georges, Guy ^a   Brinkmann, Ulrich ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Angiogenesis; Antibody cytokine fusion proteins; Chimeric extracellular receptor domains; Decoy receptor; Fc based fusion proteins; HER signaling; Immune effector cell recruitment; Review; Treatment resistance

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; AFLIBERCEPT; ANGIOPOIETIN; ATACICEPT; BEVACIZUMAB; CETUXIMAB; CYTOKINE; DALANTERCEPT; DOCETAXEL; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB; HYBRID PROTEIN; LAPATINIB; PERTUZUMAB; PODOPLANIN; PREDNISONE; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TREBANANIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; COLORECTAL CANCER; DRUG RECEPTOR BINDING; GENETIC ENGINEERING; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PROSTATE CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84869850308     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
2. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
3. Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30: 1073-1081, 2009.
4. Skerra A and Plückthun A: Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240: 1038-1041, 1988.
5. Glockshuber R, Malia M, Pfitzinger I and Plückthun A: A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29: 1362-1367, 1990.
6. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS and Whitlow M: Single-chain antigen-binding proteins. Science 242: 423-426, 1988.
7. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R and Oppermann H: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85: 5879-5883, 1988.
8. Brinkmann U, Reiter Y, Jung SH, Lee B and Pastan I: A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 90: 7538-7542, 1993.
9. Reiter Y, Brinkmann U, Lee B and Pastan I: Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol 14: 1239-1245, 1996.
10. Schmiedl A, Breitling F and Dübel S: Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli. Protein Eng 13: 725-734, 2000.
11. Buchner J, Pastan I and Brinkmann U: A method for increasing the yield of properly folded recombinant fusion proteins: singlechain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205: 263-270, 1992.
12. Simister NE and Mostov KE: An Fc receptor structurally related to MHC class I antigens. Nature 337: 184-187, 1989.
13. Roopenian DC and Akilesh S: FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715-725, 2007.
14. Kerbel RS: Tumor angiogenesis. N Engl J Med 358: 2039-2049, 2008.
15. Fischer C, Schneider M and Carmeliet P: Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis. Handb Exp Pharmacol 176: 157-212, 2006.
16. Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A and Medinger M: Biomarkers in tumor angiogenesis and antiangiogenic therapy. Int J Mol Sci 12: 7077-7099, 2011.
17. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD and Rudge JS: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398, 2002.
18. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ and Yamashiro DJ: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99: 11399-1404, 2002.
19. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ and Kandel JJ: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100: 7785-7790, 2003.
20. Fukasawa M and Korc M: Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 10: 3327-3332, 2004.
21. Teng LS, Jin KT, He KF, Zhang J, Wang HH and Cao J: Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 73: 449-456, 2010.
22. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD and McDonald DM: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165: 35-52, 2004.
23. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N and Yancopoulos GD: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 104: 18363-18370, 2007.
24. Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, Lorentz P, Jeltsch M, Alitalo K, Eriksson U, Christofori G and Pietras K: Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One 5: e14109, 2010.
25. Kopfstein L, Veikkola T, Djonov VG, Baeriswyl V, Schomber T, Strittmatter K, Stacker SA, Achen MG, Alitalo K and Christofori G: Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol 170: 1348-1361, 2007.
26. Fischer C, Mazzone M, Jonckx B and Carmeliet P: FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat Rev Cancer 8: 942-956, 2008.
27. Jin K, Shen Y, He K, Xu Z, Li G and Teng L: Aflibercept (VEGF Trap): One more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol 12: 526-532, 2010.
28. Wesche J, Haglund K and Haugsten EM: Fibroblast growth factors and their receptors in cancer. Biochem J 437: 199-213, 2011.
29. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
30. Presta M, Moscatelli D, Joseph-Silverstein J and Rifkin DB: Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 6: 4060-4066, 1986.
31. Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10: 116-129, 2010.
32. Greulich H and Pollock PM: Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 17: 283-292, 2011.
33. Plotnikov AN, Hubbard SR, Schlessinger J and Mohammadi M: Crystal structures of two FGF FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101: 413-424, 2000.
34. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G and Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem 271: 15292-15297, 1996.
35. Knights V and Cook SJ: De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 125: 105-117, 2010.
36. Korc M, Friesel RE: The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 9: 639-651, 2009.
37. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA Jr. and Heasley LE: Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small cell lung cancer cells. Mol Pharmacol 75: 196-207, 2008.
38. Knights V and Cook SJ: De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 125: 105-117, 2010.
39. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM and Goodfellow PJ: Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26: 7158-7162, 2007.
40. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M and Greulich H: Drugsensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105: 8713-8717, 2008.
41. Zhang H, Masouka L, Baker K, Sadra A, Bosch E, Brennan T, Doberstein S, Goodworth G, Hestir K, Hollenbaugh D, Long L, Qin M and Williams LT: Abstract B55, AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics Discovery, Biology and Clinical Applications, October 22-26, San Francisco, CA, 2007.
42. Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D and Heasley LE: Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res 17: 5016-5025, 2011.
43. Harding TC, Palencia S, Long L, Finer JT, Keer HN, Baker KP and Kabanaugh WM: Abstract 2597, AACR Annual Meeting 2010, Washington DC.
44. Massagué J: TGFβ in cancer. Cell 134: 215-230, 2008.
45. Goumans MJ, Liu Z and ten Dijke P: TGF-beta signaling in vascular biology and dysfunction. Cell Res 19: 116-127, 2009.
46. Cunha SI and Pietras K: ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 117: 6999-7006, 2011.
47. Niessen K, Zhang G, Ridgway JB, Chen H and Yan M: ALK1 signaling regulates early postnatal lymphatic vessel development. Blood 115: 1654-1661, 2009.
48. David L, Mallet C, Mazerbourg S, Feige JJ and Bailly S: Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961, 2006.
49. Urness LD, Sorensen LK and Li DY: Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26: 328-331, 2000.
50. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S and Li E: Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97: 2626-2631, 2000.
51. Sadick H, Riedel F, Naim R, Goessler U, Hörmann K, Hafner M and Lux A: Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-β1 as well as high ALK1 tissue expression. Haematologica 90: 818-828, 2005.
52. Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, Amundson K, Simon R, Erbersdobler A, Bergqvist S, Feng Z, Swanson TA, Simmons BH, Lippincott J, Casperson GF, Levin WJ, Stampino CG, Shalinsky DR, Ferrara KW, Fiedler W and Bertolini F: Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 71: 1362-1373, 2011.
53. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, Seehra J, Heldin CH, ten Dijke P and Pietras K: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 207: 85-100, 2010.
54. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J and Kumar R: ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 9: 379-388, 2010.
55. Hirakawa S, Hong YK, Harvey N, Schacht V, Matsuda K, Libermann T and Detmar M: Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 162: 575-586, 2003.
56. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K and Kerjaschki D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154: 385-394, 1999.
57. Martín-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S and Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial mesenchymal transition. J Cell Sci 119: 4541-4553, 2006.
58. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G and Detmar M: T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22: 3546-3556, 2003.
59. Ramirez MI, Millien G, Hinds A, Cao Y, Seldin DC and Williams MC: T1α, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev Biol 256: 61-72, 2003.
60. Cueni LN and Detmar M: Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions. Exp Cell Res 315: 1715-1723, 2009.
61. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y and Narimatsu H: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 99: 54-61, 2007.
62. Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B, Soleiman A, Birner P, Krieger S, Hovorka A, Silberhumer G, Laakkonen P, Petrova T, Langer B and Raab I: Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 15: 603-612, 2004.
63. Cueni LN, Chen L, Zhang H, Marino D, Huggenberger R, Alitalo A, Bianchi R and Detmar M: Podoplanin Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin. Blood 116: 4376-4384, 2010.
64. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M and Tsuruo T: Molecular identification of aggrus/T1α as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 278: 51599-51605, 2003.
65. Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, Moch H and Detmar M: Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol 177: 1004-1016, 2010.
66. Huang H, Bhat A, Woodnutt G and Lappe R: Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585, 2010.
67. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, Campochiaro PA, Wiegand SJ and Yancopoulos GD: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 3: 411-423, 2002.
68. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, Schadendorf D, Thurston G, Fiedler U and Augustin HG: Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333, 2009.
69. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T and Kendall R: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516, 2004.
70. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z and Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623-628, 1999.
71. Reichert JM: Antibody-based therapeutics to watch in 2011. Mabs 3: 76-99, 2011.
72. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N and Rosen LS: Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27: 3557-3565, 2009.
73. Robson EJ and Ghatage P: AMG 386: Profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 20: 297-304, 2011.
74. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, Kim M, Kim KE, Kim H, Lim NK, Jeon CJ, Lee GM, Jeon BH, Nam DH, Sung HK, Nagy A, Yoo OJ and Koh GY: Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18: 171-184, 2010.
75. Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005.
76. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
77. Huang J, Bae JO, Tsai JP, Kadenhe-Chiweshe A, Papa J, Lee A, Zeng S, Kornfeld ZN, Ullner P, Zaghloul N, Ioffe E, Nandor S, Burova E, Holash J, Thurston G, Rudge J, Yancopoulos GD, Yamashiro DJ and Kandel JJ: Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol 34: 79-87, 2009.
78. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
79. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
80. Bublil EM and Yarden Y: The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19: 124-134, 2007.
81. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
82. Riese DJ 2nd and Stern DF: Specificity within the EGF family/ERBB receptor family signaling network. Bioessays 20: 41-48, 1998.
83. Massagué J and Pandiella A: Membrane-anchored growth factors. Annu Rev Biochem 62: 515-541, 1993.
84. Saxena R and Dwivedi A: ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev 32: 166-215, 2012.
85. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F and Gianni L: Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9: 16-32, 2011.
86. Garrett JT and Arteaga CL: Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther 11: 793-800, 2011.
87. Carter CA, Kelly RJ and Giaccone G: Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Investig Drugs 18: 1829-1842, 2009.
88. Sarup J, Jin P, Turin L, Bai X, Beryt M, Brdlik C, Higaki JN, Jorgensen B, Lau FW, Lindley P, Liu J, Ni I, Rozzelle J, Kumari R, Watson SA, Zhang J and Shepard HM: Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Mol Cancer Ther 7: 3223-3236, 2008.
89. Huang Z, Brdlik C, Jin P and Shepard HM: A pan-HER approach for cancer therapy: Background, current status and future development. Expert Opin Biol Ther 9: 97-110, 2009.
90. Shepard HM, Brdlik CM and Schreiber H: Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118: 3574-3581, 2008.
91. Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, Bai X, Liu J, Jorgensen B and Shepard HM: Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Mol Med 15: 11-20, 2009.
92. Mackay F and Browning JL: BAFF: A fundamental survival factor for B cells. Nat Rev Immunol 2: 465-475, 2002.
93. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM and Ashkenazi A: Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10: 785-788, 2000.
94. Dillon SR, Gross JA, Ansell SM and Novak AJ: An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5: 235-246, 2006.
95. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, Moine P, Rossi JF, Klein B and Tarte K: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103: 3148-3157, 2004.
96. Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, Moine P, Robert N, Jourdan E, Rossi JF and Klein B: APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 83: 119-129, 2009.
97. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A and Clegg CH: TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS. Immunity 15: 289-302, 2001.
98. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM and Migone TS: BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169: 4314-4321, 2002.
99. Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, Nestorov I, Devries T, Dillon SR, Hausman D and Novak AJ: Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 14: 1105-1110, 2008.
100. Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouillé V, Nestorov I, Mordenti G, Goldschmidt H, Ythier A and Klein B: Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: A phase I study. Br J Cancer 101: 1051-1058, 2009.
101. Gayed M and Gordon C: Novel treatments for systemic lupus erythematosus. Curr Opin Investig Drugs 11: 1256-1264, 2010.
102. Buch MH and Emery P: New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 23: 245-251. 2011,
103. Hartung HP and Kieseier BC: Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 3: 205-216, 2010.
104. Davidson JA, Musk AW, Wood BR, Morey S, Ilton M, Yu LL, Drury P, Shilkin K and Robinson BW: Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother 21: 389-398, 1998.
105. Cohen J: IL-12 deaths: Explanation and a puzzle. Science 270: 908, 1995.
106. Schrama D, Reisfeld RA and Becker JC: Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5: 147-159, 2006.
107. Zafir-Lavie I, Michaeli Y and Reiter Y: Novel antibodies as anticancer agents. Oncogene 26: 3714-3733, 2007.
108. Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD and Reisfeld RA: Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res 61: 6178-6184, 2001.
109. Ebbinghaus C, Scheuermann J, Neri D and Elia G: Diagnostic and therapeutic applications of recombinant antibodies: Targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr Pharm Des 10: 1537-1549, 2004.
110. Weidle UH, Maisel D, Klostermann S, Weiss EH and Schmitt M: Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer. Cancer Genomics Proteomics 8: 211-26, 2011.
111. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D and Zardi L: Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99: 1659-1665, 2002.
112. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D and de Braud F: The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 46: 2926-2935, 2010.
113. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD and Sondel P: Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22: 4463-4473, 2004.
114. Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, González-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D and Garbe C: A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 17: 7732-7742, 2011.
115. Sharma P, Wagner K, Wolchok JD and Allison JP: Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 11: 805-812, 2011.
116. Khurshid H and Sinclair N: Use of monoclonal antibodies in oncology. Med Health R I 94: 325-328, 332, 2011.
117. Dudley ME and Rosenberg SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666-675, 2003.
118. Seliger B, Maeurer MJ and Ferrone S: Antigen-processing machinery breakdown and tumor growth. Immunol Today 21: 455-464, 2000.
119. Lev A, Novak H, Segal D and Reiter Y: Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes. J Immunol 169: 2988-2996, 2002.
120. Lev A, Noy R, Oved K, Novak H, Segal D, Walden P, Zehn D and Reiter Y: Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci USA 101: 9051-9056, 2004.
121. Oved K, Lev A, Noy R, Segal D and Reiter Y: Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 54: 867-879, 2005.
122. Novak H, Noy R, Oved K, Segal D, Wels WS and Reiter Y: Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo. Int J Cancer 120: 329-336, 2007.
123. Lanier LL: NK cell recognition. Annu Rev Immunol 23: 225-274, 2005.
124. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790, 2003.
125. González S, López-Soto A, Suarez-Alvarez B, López-Vázquez A and López-Larrea C: NKG2D ligands: Key targets of the immune response. Trends Immunol 29: 397-403, 2008.
126. Zhang T and Sentman CL: Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 71: 2066-2076, 2011.
127. Ferrucci PF, Tosti G, Pietro A, Passoni C, Pari C, Tedeschi I, Cataldo F, Martinoli C and Testori A: Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment. Curr Top Med Chem 12: 11-31, 2012.
128. Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Marie Nicolay HJ, Sigalotti L and Maio M: The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Mol Oncol 5: 164-182, 2011.
129. Belmont HJ, Price-Schiavi S, Liu B, Card KF, Lee HI, Han KP, Wen J, Tang S, Zhu X, Merrill J, Chavillaz PA, Wong JL, Rhode PR and Wong HC: Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein. Clin Immunol 121: 29-39, 2006.
130. Card KF, Price-Schiavi SA, Liu B, Thomson E, Nieves E, Belmont H, Builes J, Jiao JA, Hernandez J, Weidanz J, Sherman L, Francis JL, Amirkhosravi A and Wong HC: A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol Immunother 53: 345-357, 2004.
131. Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D and Avigan D: Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother 33: 155-166, 2010.
132. Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR and Wong HC: Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA- A*0201 complex, in patients with advanced malignancies. Clin Cancer Res 17: 7765-7775, 2011.
133. Flanagan ML, Arias RS, Hu P, Khawli LA and Epstein AL: Soluble Fc fusion proteins for biomedical research. Methods Mol Biol 378: 33-52, 2007.
134. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN and Bourne PE: The Protein Data Bank (www.pdb.org). Nucleic Acids Res 28: 235-242, 2000.
135. Accelrys Software Inc., Discovery Studio Modeling Environment, Release 3.1, San Diego: Accelrys Software Inc., 2007.